Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Illumina Stock Quote

Illumina (NASDAQ: ILMN)

Price as of April 12, 2024, 4:00 p.m. ET

Illumina Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ILMN -45.39% -62.45% -17.77% +549%
S&P +23.57% +76.22% +11.98% +261%

Illumina Company Info

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

News & Analysis

The Fool has written over 500 articles on Illumina.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.